Regulatory & Reimbursement
FDA Output, June 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in June 2026. Updated June 11.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Investors & Dealmaking
MedTech Capital Matters May 2026
We present selected private financings for May, a month in that saw several $50 million-plus rounds for medical device companies.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Pathways' Pick of the Week: Exits in Congress and FDA
Senate Health chair loses primary and FDA AI chief departs. Excerpted from Pathways’ Picks May 21: Congress, FDA Exits, Notified Body Layoffs, CPT Codes, and More.